UK Sovereign AI Fund
£500M UK government venture fund for British AI startups; backed Isomorphic Labs and CuspAI
- Government & grants
- London
- Type
- Government & grants
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- AI & Data, Deeptech, Healthtech, Biotech & Life Sciences
- Cheque size
- £1M–£10M equity
- Fund size
- £500M
- Founded
- 2026
- Website
- sovereignai.gov.uk
Sovereign AI is the UK government's £500M venture fund for scaling British AI companies, run under the Department for Science, Innovation and Technology's AI Opportunities Action Plan and launched in 2026. It writes equity cheques of £1M to £10M from pre-seed through to growth, and pairs capital with up to one million GPU hours of sovereign compute, fast-tracked visas and access to grants, datasets and contracts. Priority areas are compute and infrastructure, foundation models, AI in health and life sciences, scientific discovery, and trust and safety. Its portfolio includes Isomorphic Labs and CuspAI, both listed in this directory, alongside Callosum, Basecamp Research and others.
Team
- James Wise, Chair LinkedIn
- Suzanne Ashman, Managing Partner LinkedIn
- Joséphine Kant, Investment Partner LinkedIn
Portfolio in the directory
← All investors · Is this your organisation? Request an update
More investors in the directory
CPP Investments
Canada's national pension fund manager; growth investor in Octopus Energy and 9fin
CPI
UK deep tech innovation centre whose CPI Enterprises arm backs pre-seed and seed start-ups; backed Qualus and DEScycle
CapitalG
Alphabet's independent growth fund; led Monzo's 2024 round and backed Isomorphic Labs
BOND
San Francisco growth-stage venture firm founded by Mary Meeker; backed ElevenLabs and Multiverse
Y Combinator
US accelerator investing $500k per startup; alumni include Encord, LemFi, Prolific and Kaya
Tiger Global
New York investment firm backing private tech companies; led rounds for BVNK, Checkout.com and Nothing
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.